The US Food and Drug Administration (FDA) has announced the approval of Sanofi and Regeneron’s interleukin (IL)-4 and IL-13 ...

The FDA has approved the first treatment for schizophrenia that targets cholinergic receptors rather than dopamine receptors.

UNICEF has reached an agreement with mpox vaccine manufacturer Bavarian Nordic to supply one million doses of the shot for ...

The US FDA placed a full clinical hold on two diabetes trials for Biomea’s menin inhibitor after reports of liver toxicity.

The collaboration aims to utilise Tempus’ real-world data and biological modelling to enhance the development of Takeda’s ...

Phare Bio has received up to $27m from the Advanced Research Projects Agency for Health (ARPA-H) to advance its drug ...

Opioid use disorder (OUD) is a chronic neurological disorder characterised by the compulsive, repeated use of opioids, ...

Direct-to-patient communication is emerging as a powerful solution to the challenges of non-adherence to medication. By ...

The FDA has approved AstraZeneca's Tagrisso (osimertinib) to treat adults with unresectable stage III EGFR-mutated NSCLC.

Biocon has entered a partnership with Tabuk Pharmaceuticals for the commercialisation of glucagon-like peptide-1 (GLP-1) ...

Safety processes and regulations apply to custom-made medicines, which differ from traditional pharmacies. Now, however, ...

GlobalData tracks 20 drugs in development for Acromegaly by 19 companies/universities/institutes. The top development phase for Acromegaly is preclinical, with six drugs in that stage.